ArticleJournal for immunotherapy of cancer2020
Predictive value of integrated
Article in Journal for immunotherapy of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- The efficacy and safety of PD-1 inhibitors combined with chemotherapy treatment for advanced esophageal cancer: a network meta-analysis.Frontiers in medicine · 2024Pooled it
- [European journal of nuclear medicine and molecular imaging · 2022Trial
- Glycolysis‑driven immunosuppression in gastric cancer: Metabolic crosstalk between tumor cells and the immune microenvironment (Review).International journal of oncology · 2026Review
- Early Tumor Shrinkage and Depth of Response as Predictive Markers of Treatment Response and Prognosis in Solid Tumors.Cancer medicine · 2025Review
- FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Clinical impact of inflammatory and nutrition index based on metabolic tumor activity in non‑small cell lung cancer treated with immunotherapy.Oncology letters · 2024Article
- Immune checkpoint inhibition: a future guided by radiology.The British journal of radiology · 2023Review
- MRI techniques for immunotherapy monitoring.Journal for immunotherapy of cancer · 2022Review
- Prospective assessment usingScientific reports · 2022Article
- CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Advantages of FBPA PET in evaluating early response of anti-PD-1 immunotherapy in B16F10 melanoma-bearing mice: Comparison to FDG PET.Frontiers in oncology · 2022Article
- Review
- Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [Journal of clinical medicine · 2021Review
- Predictive value of 3'-deoxy-3'-Journal for immunotherapy of cancer · 2021Article
- Molecular Imaging and the PD-L1 Pathway: From Bench to Clinic.Frontiers in oncology · 2021Review
- Positron Emission Tomography-Based Response to Target and Immunotherapies in Oncology.Medicina (Kaunas, Lithuania) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe early response to treatment with immune-checkpoint inhibitors is difficult to evaluate. We determined whether changes in integrated [
methodsTwenty-five patients with previously treated NSCLC were enrolled prospectively and underwent
resultsThe disease control rate was 64%. Patients with non-progressive disease (non-PD) had significantly decreased TLG, increased ADC
conclusionsA combination of ΔTLG and ΔADC TRIAL REGISTRATION NUMBER: UMIN 000020707.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.